Chinese Expert Consensus on the Diagnosis and Treatment of Platinum-Resistant Recurrent Ovarian Cancer (2025 Edition)
Among gynecological malignancies, ovarian cancer has the most grim prognosis, primarily due to its high recurrence risk after treatment. Multiple recurrences lead to increased drug resistance. Recurrent ovarian cancer is classified into platinum-sensitive and platinum-resistant types, and treatment strategies depend on the patient's sensitivity to platinum-based chemotherapy. For patients with platinum-sensitive recurrent ovarian cancer, the use of platinum-based chemotherapy combined with targeted therapy (such as PARP inhibitors or bevacizumab) has been shown to prolong survival.
Release time:
2025-07-08
Source:







